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ABSTRACT
Introduction Panic disorder is among the most 
prevalent anxiety diseases. Although psychotherapy is 
recommended as first- line treatment for panic disorder, 
little is known about the relative efficacy of different types 
of psychotherapies. Moreover, there is little evidence 
concerning the effectiveness of different formats of 
major psychotherapeutic types, such as cognitive–
behavioural therapy (CBT). In this protocol, we present 
an overarching project consisting of two systematic 
reviews and network meta- analyses (NMA) to shed light 
on which psychotherapy (NMA-1), and specifically, which 
CBT delivery format (NMA-2) should be considered most 
effective for adults suffering from panic disorder with or 
without agoraphobia.
Methods and analyses Starting from a common pool 
of data, we will conduct two systematic reviews and 
NMA of randomised controlled trials examining panic 
disorder. A comprehensive search will be performed in 
electronic databases MEDLINE, Embase, PsycINFO and 
the Cochrane Register of Controlled Trials—CENTRAL 
from database inception to 1 January 2021 to identify 
relevant studies. A systematic approach to searching, 
screening, reviewing and data extraction will be applied. 
Titles, abstract and—whenever necessary—full texts will 
be examined independently by at least two reviewers. 
The quality of the included studies will be assessed using 
the revised Cochrane risk of bias tool V.2. The primary 
efficacy outcome will be anxiety symptoms at study 
endpoint. The primary acceptability outcome will be all- 
cause discontinuation, as measured by the proportion of 
patients who had discontinued treatment for any reason 
at endpoint. Data will be pooled using a random- effects 
model. Pairwise and NMA will be conducted.
Ethics and dissemination No ethical approval is 
necessary for these two studies, as there will be 
no collection of primary data. The results will be 
disseminated through peer- reviewed publications and 




A panic attack is a spontaneous and unex-
pected abrupt surge of intense fear or 
discomfort with a rapid onset and that 
reaches a peak within 10 min. The main char-
acteristic of panic disorder is the recurrence 
of panic attacks. In order to be diagnosed 
with panic disorder, according to Diagnostic 
and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM- V),1 at least one episode 
must be followed by 1 month (or more) of 
persistent concern about having additional 
attacks, worry about the implications of the 
attack (or its consequences), or a significant 
change in behaviour related to the attacks. 
Panic disorder is a common disorder that 
presents across the spectrum of severity, with 
Strengths and limitations of this study
 ► Network meta- analyses compare, in the context 
of a systematic review, multiple treatments using 
both direct comparisons of interventions within ran-
domised controlled trials and indirect comparisons 
across trials based on a common comparator.
 ► We will comprehensively assess the efficacy and ac-
ceptability of all available psychotherapies for panic 
disorder with or without agoraphobia in adults at the 
end of the acute treatment, and subsequently, the 
comparative efficacy and acceptability of different 
types of cognitive–behavioural therapy delivery for-
mats, for the same population.
 ► These studies will inform policy and clinical decision 
making. Such information can be particularly rele-
vant in resource- limited settings, carrying practice- 
changing potential.
 ► Dissertations and trials on maintenance and relapse 
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very large numbers of people suffering from considerable 
functional impairment and decrease in quality of life as a 
result. Indeed, the life- time prevalence of panic disorder 
ranges between 1.1% and 3.7%.2 In primary care settings, 
panic symptoms have been reported to have a prevalence 
of around 10%.3
In around a quarter of patients, panic disorder is accom-
panied by agoraphobia (avoidance of situations where 
escape would be difficult when panic attacks occur).2 
Agoraphobia is anxiety about being in places or situations 
from which escape might be difficult or embarrassing, or 
in which help may not be available in the event of having 
a panic attack. The prognosis of panic disorder in wors-
ened by the coexistence of agoraphobia.2 There are 
several risk factors that predict the development of agora-
phobia in people suffering from panic disorder, among 
them female gender, more severe dizziness during panic 
attacks, dependent personality traits and social anxiety 
disorder.4
In recent decades, a large number of trials have been 
conducted and the effects of psychological treatments on 
panic examined. These studies have clearly shown that 
psychological treatments have beneficial effects, in terms 
of symptom reductions and increased well- being.5 In 
particular, there is abundance of evidence on the effec-
tiveness of cognitive–behavioural therapy (CBT) to treat 
panic disorder.6–8 Dozens of randomised controlled trials 
(RCTs) have examined different CBT treatment formats 
in the last decades. As an alternative to the classical 
individual face- to- face format, CBT for panic disorder 
can be administered by telephone, in a digital- assisted 
modality, to groups of people or as self- help therapy in 
which patients work through a standardised protocol 
independently. The protocol can be in book format or 
available on the internet. Self- help therapy can either 
be guided (ie, involving a professional therapist) or 
unguided (ie, providing no professional guidance to the 
patient using the materials).9
Because of this huge body of knowledge, it is important 
that the results of these studies are summarised and 
integrated in meta- analytical studies. This has been 
done during the previous 20 years, as the evidence base 
grew over time.6 10–12 Although meta- analyses are seen 
as representing the pinnacle of a hierarchy of evidence 
used to inform clinical practice, the trustworthiness of 
their output is not to be taken for granted, and specific 
methodological tools exist to challenge their results.13 
As for many other research areas, some doubts on the 
reporting quality of meta- analyses on anxiety treatment 
have been put forward as well.14
Thanks to the advent of network meta- analyses (NMA), 
it is now possible to compare, in the context of a system-
atic review, multiple treatments (ie, three or more) 
using both direct comparisons of interventions within 
RCTs and indirect comparisons across trials.15 A system-
atic review and NMA on the psychological treatment of 
panic disorder7 was published in the Cochrane Library; 
although exhaustive and methodologically sound, this 
NMA did not take into account all available psycho-
therapies, did not consider delivery methods other 
than face- to- face sessions and did not consider drug 
therapy with antidepressants and/or benzodiazepines as 
comparators. Furthermore, its search was last updated at 
the beginning of 2015. As the matter of psychotherapy 
for mental health problems is dynamic and controver-
sial16 17 and the number of trials is constantly increasing, 
it is important to keep a good, up- to- date overview of 
the field. Furthermore, there is evidence warning about 
the relatively short time on which a systematic reviews 
directly relevant to clinical practice can be considered 
outdated.18
Against this background, we will conduct two fully 
updated and state- of- the- art systematic reviews and NMA 
addressing both efficacy and acceptability of psychothera-
pies delivered in any treatment format for adults suffering 
from panic disorder with or without agoraphobia, and 
the efficacy and acceptability of different types of CBT 
delivery formats for adults suffering from the aforemen-
tioned condition.
Aim and objectives
The overall aims of these systematic reviews and NMA are:
1. To evaluate the effectiveness and acceptability of differ-
ent types of psychotherapies for adults suffering from 
panic disorder with or without agoraphobia (NMA-1).
2. To evaluate the efficacy and acceptability of differ-
ent types of CBT delivery formats for adults suffer-
ing from panic disorder with or without agoraphobia 
(NMA-2).
The PICO format for the two research questions is 
displayed in table 1.
Table 1 PICO format for the two research questions
NMA-1: psychotherapies for panic disorder NMA-2: CBT delivery formats for panic disorder
P=adults suffering from panic disorder with or without 
agoraphobia
P=adults suffering from panic disorder with or without 
agoraphobia
I- C=any psychotherapy; inactive/active comparators I- C=CBT delivered in any format; inactive comparators
O=1) anxiety symptoms reduction (efficacy); 2) all- cause 
treatment discontinuation (effectiveness)
O=(1) anxiety symptoms reduction (efficacy); (2) all- cause 
treatment discontinuation (effectiveness)
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METHODS
The project started on 1 March 2020 and it is expected to 
be completed by 31 August 2021. The protocol is reported 
in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses (PRISMA) proto-
cols checklist19 20 (online supplemental file online).
Types of studies
We will include RCTs on psychotherapies for panic 
disorder with or without agoraphobia. We will include 
RCTs that tested combination therapies of psychotherapy 
and drug, as long these combinations were balanced 
within the same trial (eg, arm A: alprazolam +CBT; arm B: 
alprazolam +waiting list). We will include RCTs comparing 
psychotherapy against drug treatment (irrespective of 
drug class and dosage) or psychotherapy against drug 
treatment and/or placebo pill or a type of psychotherapy 
against another type of psychotherapy. Trials designed 
as maintenance treatment or relapse prevention will be 
excluded. We will set no limits in term of duration of 
treatment, number of sessions and minimal number of 
participants.
Types of participants
We will include RCTs in which participants are aged 18 
or older, of both sexes, with a primary diagnosis of panic 
disorder with or without agoraphobia according to any 
standardised diagnostic criteria, such as the DSM or Inter-
national Classification of Diseases . Patients must be in 
the acute phase of their disorder at the time of enrol-
ment in the RCT. We will include RCT that enrolled 
exclusively participants diagnosed with panic disorder 
with or without agoraphobia. Where trials include partic-
ipants suffering from an array of anxiety disorders, the 
data will be included if data on participants with a diag-
nosis of panic disorder with or without agoraphobia can 
be extracted separately. We will also consider including 
trials in which participants have a secondary diagnosis 
of comorbid general psychiatric (eg, major depression) 
or organic disorder. All research settings, such as outpa-
tient clinics, inpatient services, community clinics, will be 
included.
Types of interventions
In NMA-1, we will consider any kind of psychotherapy. 
We define psychotherapy as the informed and intentional 
application of clinical methods derived from established 
psychological principles to assist participants with their 
behaviours, cognitions and emotions in directions that 
the participants deem desirable (modified from Camp-
bell et al21). Therapies can be delivered by any therapist 
(psychologist, psychiatrist, nurse, social worker, etc, but 
also lay health counsellors and paraprofessionals) as long 
as they were trained to deliver the therapy, or as self- help. 
As for standard CBT protocols, we expect most of the 
interventions to last from 422 to 12 sessions,23 delivered on 
a weekly basis, although we will consider psychotherapy 
interventions of any length. In line with the meta- analysis 
from Pompoli et al,7 we will consider the nodes for the 
psychotherapies displayed in table 2, leaving open the 
possibility to add further intervention nodes if other types 
of psychotherapy will be detected during the screening 
phase.
Different treatment formats will be allowed, including 
individual or group face to face, telephone, guided self- 
help (through the internet or not) and couple therapy. 
We will also include self- guided interventions without 
any professional support (remote/unguided self- help) or 
digital- assisted therapies (table 3).
Starting from the same pool of data considered for 
NMA-1, in the second project (NMA-2) we will specifically 
focus only on those trials that evaluated CBT, comparing 
the efficacy and effectiveness of the different treatment 
delivery formats. We defined CBT as a therapy in which 
cognitive restructuring was one of the core compo-
nents.24–26 Cognitive restructuring is aimed at evaluating, 
challenging and modifying a patient’s dysfunctional 
beliefs. In NMA-2, we will focus on CBT only (not consid-
ering all of the other types of psychotherapy) because the 
homogeneity of the intervention is essential to inform on 
the efficacy of the different treatment modalities. Further-
more, being CBT the most recommended and studied 
form of psychotherapy for panic disorder,27 information 
regarding its efficacy when administered in different 
treatment modalities will probably have the best impact 
on policy and clinical decision making.
In NMA-2, the intervention nodes will be those 
displayed in table 3.
Types of controls
In the first NMA (NMA-1), we will consider the nodes for 
the control groups as for Pompoli et al,7 plus a node for 
antidepressant medications, a node for benzodiazepine 
medications and a node for placebo pill. For the second 
NMA (NMA-2), we will not consider antidepressants and 
benzodiazepine. Control groups and their definitions are 
displayed in table 4.
Types of outcome measures
The primary efficacy outcome will be anxiety symptoms 
at study endpoint.
The standardised mean difference (SMD) will be used 
as a measure of effect size in efficacy outcome. We will 
consider scale endpoint data as first choice, since we 
expect no baseline imbalances resulting from the trials 
randomisation process. As an alternative, we will consider 
mean change scores in anxiety symptoms from baseline 
to post- treatment. It has been shown that combining 
endpoint and change data in meta- analysis is generally 
valid.28 We will select one outcome measure for each 
study using the following algorithm7: scales specific for 
panic disorder (Panic Disorder Severity Scale >Panic 
and Agoraphobia Scale > Anxiety Sensitivity Index- 
Revised >Anxiety Sensitivity Index > Agoraphobic 
Cognitions Questionnaire>Body Sensations Question-
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Impression Severity Scale >Clinical Global Impression- 
Improvement Scale>10Global Assessment Scale> Global 
Assessment of Functioning>other); scales specific for 
agoraphobia only (Fear Questionnaire- Agoraphobia 
Subscale >Fear Questionnaire- Global>Mobile Inventory 
for Agoraphobia- Avoidance- Alone>Mobility Inventory 
-Avoidance- Accompanied > other); scales specific for 
panic attacks (panic frequency >panic severity >other) 
(table 5).
Global Assessment Scale Clinical Global 
Impression- Improvement scale>GAS > GAF>other); 
scales specific for agoraphobia only (FQ- ag 
>FQ- global>MI AAL>MIAAC>other); scales specific for 
panic attacks (panic frequency>panic severity>other) 
(table 5).
The primary acceptability outcome will be all- cause 
discontinuation, as measured by the proportion of 
patients who had discontinued treatment for any reason 
at endpoint.
All outcomes will refer to acute phase treatment (study 
endpoint), which normally last 2–6 months.
Where different symptom severity rating scales were 
used for the purpose of pooling results, we will choose 
the single best available outcome measure according 
to a hierarchy based on psychometric properties and 
frequency of use.
Search strategy
Four bibliographical databases will be searched 
(MEDLINE, Embase, PsycINFO and the Cochrane 
Register of Controlled Trials- CENTRAL) from database 
inception to 1 January 2021, to identify RCTs examining 
the effects of psychotherapy for panic disorder with or 
without agoraphobia, compared with any other interven-
tion or control condition. No language or geographical 
restrictions will be applied. In the search strings, we will 
combine index terms and text words indicative of panic 
disorder with or without agoraphobia and psychothera-
pies, with filters for RCTs. We will also add the references 
of trials through other sources, such as other meta- 
analyses, and contact with other researchers. The full 
search strategy is provided in online supplementary file. 
A PRISMA flow chart29 will be used to present the search 
strategy used in these NMA.
Study selection and data extraction
Selection of trials
All records from all sources will be entered into Endnote, 
and duplicates will be removed. All resulting records will 
be checked by two independent researchers (DP and 
EK). If one of the researchers will indicate that a record 
possibly contained a study meeting the inclusion criteria, 
the full text of that paper will be retrieved. The full texts 
of the papers will be read by the same researchers for final 
inclusion. Any disagreements will be resolved by a third 
review author (CB or PC).
When multiple publications come from the same data 
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Data extraction
Four independent reviewers (DP, PC, EK and MS) will 
extract the data from the original reports using stan-
dardised data extraction forms, characteristics of the 
participants (recruitment methods, type of diagnosis, 
target group), of the therapies (format and number of 
sessions of the therapies, for type of therapy), for studies 
including pharmacotherapy we will rate the type and for 
studies including a control group we will rate the type of 
control group. We will also report where the study was 
conducted and in which year it was published. We will also 
rate other characteristics of the included studies: source 
of patient recruitment, diagnosis (panic disorder without 
agoraphobia only, panic disorder with or without agora-
phobia, agoraphobic patients only), age group, mean age, 
the percentage of women participating, percentage of 
agoraphobic participants in the trial, comorbidity (mental 
or general disorders), intervention format, number of 
sessions of the intervention, presence/absence of phar-
macotherapy coadministration, type of control condition, 
country where the RCT was carried out, year of publica-
tion, baseline scores on anxiety rating scales.
Any disagreements will be resolved by consulting a fifth 
review author (CB).
Risk of bias assessment
We will assess the risk of bias (RoB) in included studies 
using the Cochrane’s second version of ‘RoB’ tool for 
randomised trials (RoB V.2).30 We will assess RoB for each 
study that contributes to the primary outcomes at post 
intervention. Two review authors (DP and EK) will inde-
pendently use the RoB V.2 signalling questions to form 
judgments of material RoB for the following five domains: 
(1) bias arising from the randomisation process; (2) bias 
due to deviations from intended interventions; (3) bias 
due to missing outcome data; (4) bias in measurement 
of outcome and (5) bias in selection of the reported 
outcome.
We will not consider the following items in the domain 
number 2 (‘bias due to deviations from intended inter-
ventions’): 2.1–2.2 in the subsection named ‘effect of 
assignments to intervention’ and 2.1–2.2 in the subsection 
Table 3 Treatment delivery formats and their definitions
Treatment delivery formats Definition
Individual format The psychotherapy is delivered by the therapist in a face- to- face individual 
setting.
Group format The psychotherapy is delivered by the therapist in a face- to- face group 
setting.
Guided self- help A psychotherapy in which a professional therapist is involved in the 
treatment process, offering guidance to the patient using the self- help 
materials (administered through the internet or other media, such as a book).
Unguided self- help A psychotherapy in which no professional guidance is provided to the patient 
using the self- help materials (internet based or not).
Digital assisted A psychotherapy format that uses technology to deliver some aspects of 
psychotherapy or behavioural treatment directly to patients via interaction 
with smartphone applications, computer programmes, or delivered via the 
Internet.
Telephone A psychotherapy format that uses the telephone to deliver psychotherapy or 
behavioural treatment directly to patients.
Table 4 Control conditions and their definitions
Control group Definition
No treatment/-
reatment as usual 
(NT/TAU)* †
Participants receive assessment 
only with or without simple provision 
of informational material or minimal 
therapist contact or both, and they 
know that they will not receive the 
active treatment in question after the 
trial. The participants in this condition 
are usually allowed to seek treatment 
as available in the community; 
when such additive treatments are 
substantive, we will include such trials 
only if it is balanced between the two 
arms to be compared.
Waiting list (WL)* † Participants receive assessment, 
with or without simple provision of 
informational material or minimal 
therapist contact or both and they 
know that they will receive the active 





Participants receive a face- to- face 
inactive intervention that can be 
perceived both as ineffective or 
effective.
Placebo (PL)*† Placebo pill.




*Control conditions for the NMA-1.
†Control conditions for the NMA-2.
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named ‘effect of adhering to intervention’. These partic-
ular biases were referred to as ‘performance biases’ in 
the original Cochrane tool for assessing RoB in RCTs.31 
Since ‘blinding of participants and personnel to treat-
ment allocation’ is not possible in psychotherapy trials, 
we will not assess the aforementioned items to avoid all 
the trials resulting to be at ‘high RoB’ by default. Thus, 
domain 2 will be limited to the evaluation of the type of 
statistical analysis that was carried out (‘intention- to- treat 
(ITT)’, ‘modified ITT’, ‘per protocol’, ‘as treated’). On 
the other hand, to better understand the methodological 
validity of the included RCTs and to enable an examina-
tion of research gaps, we will consider in the ‘RoB’ assess-
ment three additional items, consistently with two recent 
Cochrane Reviews on psychotherapy32 33: (1) Evaluating 
therapist qualifications: to check whether the profes-
sionals involved in the study were adequately trained and 
supervised to deliver the interventions; (2) Intervention 
implementation fidelity: adherence to intervention’s 
manual, which should lead to greater consistency among 
therapists and clearer distinction from control conditions 
and (3) Therapist allegiance: to state whether the profes-
sionals that delivered the interventions had beliefs and 
investment in benefit for the active arm of intervention 
over control arm/s.
RoB V.2 allows for a judgement of overall RoB for each 
included study: low RoB; some concern of bias; or high 
RoB. We will assign a rating of ‘low RoB’ to studies consid-
ered at low RoB for all five domains for the specific result. 
We will assign a rating of ‘some concern of bias’ to studies 
we judge to be at high RoB in at least one domain for the 
result in question. We will assign a rating of ‘high RoB’ to 
studies where there is a high RoB in at least one domain 
for a result or we judge the study to have some concerns 
for multiple domains in a way that substantially lowers 
confidence in the result.30
Any disagreements will be resolved by a third review 
author (CB or PC). We will present completed ‘RoB’ 
tables and justifications for each judgement in the 
published review.
Assessment of the strength of the body of evidence
To assess the overall strength of evidence, we will use the 
Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) system for NMA through the 
CINeMA application (http:// cinema. ispm. ch/).34 35 As in 
pairwise meta- analyses, we will apply the GRADE system 
to direct evidence (ie, data with head- to- head compari-
sons). When only indirect evidence will be available, 
we will use the NMA estimate and evaluate the shortest 
indirect pathway with the largest number of trials. The 
GRADE approach classifies evidence as high, moderate, 
low or very low quality based on considerations of RoB, 
consistency, directness, precision and publication bias.36
Table 5 Hierarchy of symptom severity measurement scales
Hierarchy Symptom severity rating scales Abbreviation
1 Panic Disorder Severity Scale PDSS
2 Panic and Agoraphobia Scale PAS
3 Anxiety Sensitivity Index- Revised ASI- R
4 Anxiety Sensitivity Index ASI
5 Agoraphobic Cognitions Questionnaire ACQ
6 Body Sensations Questionnaire BSQ
7 Other scales specifically focused on panic disorder




10 Global Assessment Scale GAS
11 Global Assessment of Functioning GAF
12 Other global symptoms scales
13 Fear Questionnaire- Agoraphobia Subscale FQ- agoraphobia
14 Fear Questionnaire- Global FQ global
15 Mobile Inventory for Agoraphobia-
Avoidance- Alone
MI- AAL
16 Mobility Inventory- Avoidance- Accompanied MIAAC
17 Other scales specifically focused on agoraphobia
18 Panic frequency
19 Panic severity
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Missing data
When relevant outcomes are not reported, we will ask 
trial authors to supply the data. In the absence of data 
from authors, we will employ validated statistical methods 
to impute missing outcomes, with due consideration of 
the possible bias of these procedures, in accordance with 
the Cochrane Handbook for Systematic Reviews of Inter-
ventions37 and with www. missingdata. org. uk. When SDs 
are not reported and not supplied by authors on request, 
we will calculate them based on other measures reported 
in the study, for example, SEs, t- statistics or P values, 
according to Altman.38 If this is not possible, we will use 
the correlation coefficients of other studies included in 
the analysis to calculate the SDs, or substitute them with 
a mean of those reported in other trials in the review, 
provided that they employed the same rating scale.37 39
Statistical analysis
For each of the two projects, we will perform standard 
pairwise meta- analyses with a random- effects model for 
every comparison with at least two studies. We will use 
the random- effects approach, as we expect considerable 
heterogeneity. If a sufficient number of clinically similar 
studies is available, we will perform, for each outcome, 
a NMA with a random- effects model in a frequentist 
framework, using the STATA 16.1 "Special Edition" (SE) 
mvmeta package. For the continuous outcomes (effi-
cacy), we will pool the mean differences between treat-
ment arms at endpoint if all trials measured the outcome 
using the same rating scale, otherwise we will pool SMDs.
We will test for publication bias using Egger test40 of the 
intercept to quantify the bias captured by the funnel plot 
and to test whether it is statistically significant.
For the dichotomous outcome (acceptability), we will 
calculate ORs with a 95% CI for each study and then pool 
these.
Transitivity is a basic and fundamental assumption to 
perform an NMA. This assumption is met when effect 
modifiers are equally distributed across the comparisons. 
All studies included will be similar in terms of characteris-
tics of participants, study design and outcomes, therefore, 
we expect that the assumption of transitivity will be met, 
and that all treatments included in the network can be 
considered ‘exchangeable’ (as if all of them were part of 
a large, multiarm trial). Transitivity is a logical construct, 
whose statistical counterpart is indicated as coherence, 
which evaluates the statistical disagreement between 
direct and indirect evidence of a treatment comparison.41 
We will evaluate this assumption by different means. We 
will extract key study characteristics judged to be potential 
effect modifiers, namely: number of participants included, 
percentage of agoraphobic participants, baseline panic 
frequency and number of sessions of the intervention. 
We will compare their distribution across comparisons 
in the network. Along with this qualitative evaluation of 
transitivity from a clinical and methodological viewpoint, 
we will also assess this assumption statistically.
We will statistically evaluate the presence of incoher-
ence by comparing direct and indirect evidence within 
each closed loop42 and comparing the goodness of fit for 
an NMA model that assumes consistency with a model that 
allow for inconsistency in ‘design by treatment interac-
tion model’ framework43–45 by using the Stata commands 
mvmeta15 and ifplot46 and the Stata network suite.15 
If there is evidence of inconsistency, we will investigate 
this further using a node- splitting47 approach between 
comparisons.
We will calculate a treatment hierarchy by means of 
surface under the cumulative ranking curve and mean 
ranks.48 Studies that compare two or more formats of 
similar psychotherapeutic interventions will be included 
in meta- analysis by combining group arms into a single 
group37 only if the trial includes a control condition, 
otherwise the RCT will be excluded as it cannot contribute 
to the network.
We will calculate dichotomous data on a strict ITT 
basis, considering the total number of randomised 
patients as denominator. Where participants had been 
excluded from the trial before the endpoint, we will 
assume that they experienced a negative outcome by the 
end of the trial. For continuous variables, we will apply 
a loose ITT analysis, whereby all the participants with at 
least one post- baseline measurement were represented 
by their last observations carried forward . For RCTs that 
implemented a per protocol analysis we will consider 
completers data, with due consideration of potential 
biases, including number and timings of drop- outs in 
each arm.
For pairwise meta- analyses, we will assess heteroge-
neity by visual inspection of forest plots, and using the 
I2 statistics, following the interpretation suggested by 
the Cochrane handbook37: 0%–40%: might not be 
important; 30%–60%: may represent moderate hetero-
geneity; 50%–90%: may represent substantial heteroge-
neity; 75%–100%: considerable heterogeneity. For the 
NMA, common heterogeneity across all comparisons49 
will be assumed and estimated in each network. Hetero-
geneity of the network will be evaluated by the common 
τ2, by comparing it with its empirical distributions.50 To 
verify the transitivity assumption according to which 
effect modifiers are similarly distributed across compari-
sons in the network, we will compile a table of important 
trial and patient characteristics and visually inspect the 
similarity of factors we consider likely to modify treatment 
effect, for each comparison. We will also assess the inclu-
sion and exclusion criteria of every trial in the network 
to ensure that patients, trial protocols, etc are similar. 
Furthermore, in addition to the description of study char-
acteristics in the aforementioned table, we will deepen 
the characterisation of every intervention by producing 
a detailed adjunctive table where we will describe each 
intervention and give information on the reference 
intervention manuals/important theoretical articles. 
An example is reported in online supplementary file. 
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transitivity- threatening differences between interventions 
considered for the same node.
Sensitivity analyses
 ► A sensitivity analysis will be conducted to explore 
the effects of the RCTs missing data imputation tech-
niques on outcomes. In the analysis, we will exclude 
the trials which data were imputed according to the 
strategies described in the above paragraph ‘missing 
data’.
 ► A second sensitivity analysis will be conducted in case 
of high statistical heterogeneity (I2 >75%) to explore 
the putative effects of the study quality assessed 
through the RoB V.2 on heterogeneity. In the analysis, 
we will exclude the trials judged to be at ‘high RoB’.
Patient and public involvement
Patients and the public were not involved in the design of 
this review protocol.
ETHICS AND DISSEMINATION
These two systematic reviews and network meta- analyses 
will be published separately in peer- reviewed journals. 
The results of these investigations will be disseminated 
electronically and in print, as well presented as abstracts 
and/or personal communications during national and 
international conferences. Since no primary data collec-
tion will be undertaken, no additional formal ethical 
assessment and informed consent are required.
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